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Background:  Recent clinical trials have found no benefit from statin therapy among renal failure patients undergoing hemodialysis. Whether 
patents with moderate chronic kidney disease (estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73m2) benefit from statin therapy is 
uncertain, particularly among those without hyperlipidemia or known cardiovascular disease, a group where prior data are sparse and inconsistent.
Methods and Results:  We analyzed data from the JUPITER trial, a primary prevention study of rosuvastatin 20 mg compared to placebo 
among men and women free of cardiovascular disease who had LDLC < 130 mg/dL and hsCRP > 2 mg/L and were followed for a median of 1.9 
years (maximal follow-up 5.0 years). Compared to the 14,528 trial participants with normal renal function, the 3,267 with chronic kidney disease 
had significantly higher vascular event rates (HR 1.54, 95%CI 1.23-1.92, P = 0.0002). Among those with chronic kidney disease, rosuvastatin was 
associated with a 45 percent reduction in risk of myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization, or 
confirmed cardiovascular death (HR 0.55, 95%CI 0.38-0.82, 5-year number needed to treat [NNT] = 14, P = 0.002). A similar risk reduction was 
observed among those with normal renal function (HR 0.57, 95%CI 0.45-0.72, 5-year NNT = 35, P < 0.001). Rosuvastatin reduced total mortality 
44 percent among those with chronic kidney disease (HR 0.56, 95% CI 0.37-0.85, P=0.005). Median LDLC and hsCRP reductions as well as side 
effect profiles associated with rosuvastatin were similar among those with and without chronic kidney disease at study entry. No adverse effects of 
rosuvastatin on eGFR were observed over time.
Conclusions:  Rosuvasatatin is a safe and effective agent to reduce first ever cardiovascular events and all-cause mortality among men and 
women with low LDLC, elevated hsCRP, and concomitant evidence of chronic kidney disease.
